Bio Historical Income Statement
| BPTH Stock | USD 0.80 0.02 2.44% |
Historical analysis of Bio Path income statement accounts such as Interest Expense of 31.2 K, Selling General Administrative of 2.4 M or Total Revenue of 0.0 can show how well Bio Path Holdings performed in making a profits. Evaluating Bio Path income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bio Path's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bio Path Holdings latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bio Path Holdings is a good buy for the upcoming year.
Bio |
About Bio Income Statement Analysis
Bio Path Holdings Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bio Path shareholders. The income statement also shows Bio investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bio Path Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bio Path Holdings. It is also known as Bio Path overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Bio Path's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. As of now, Bio Path's Research Development is increasing as compared to previous years. The Bio Path's current Reconciled Depreciation is estimated to increase to about 198.9 K, while Depreciation And Amortization is projected to decrease to under 77.9 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 3K | 33K | 52K | 32.5K | Interest Income | 3K | 33K | 52K | 31.0K |
Bio Path income statement Correlations
Click cells to compare fundamentals
Bio Path Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Path income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 230K | 151K | 161K | 178K | 82K | 77.9K | |
| Selling General Administrative | 4.1M | 4.3M | 4.5M | 4.7M | 4.1M | 2.4M | |
| Gross Profit | (230K) | (151K) | (161K) | (178K) | (160.2K) | (152.2K) | |
| Other Operating Expenses | 8.7M | 10.9M | 10.4M | 13.9M | 15.8M | 16.6M | |
| Operating Income | (8.7M) | (10.9M) | (10.4M) | (13.9M) | (15.8M) | (15.1M) | |
| Ebit | (8.7M) | (10.9M) | (10.4M) | (13.9M) | (15.8M) | (15.1M) | |
| Ebitda | (8.5M) | (10.7M) | (10.3M) | (13.7M) | (15.8M) | (15.0M) | |
| Cost Of Revenue | 230K | 151K | 161K | 178K | 204.7K | 194.5K | |
| Total Operating Expenses | 8.7M | 10.9M | 10.4M | 13.9M | 15.8M | 16.6M | |
| Income Before Tax | (8.6M) | (10.9M) | (10.4M) | (13.9M) | (16.1M) | (15.3M) | |
| Total Other Income Expense Net | 94K | 26K | 3K | 33K | (235K) | (223.3K) | |
| Net Income | (8.5M) | (10.9M) | (10.4M) | (13.8M) | (16.1M) | (15.3M) | |
| Income Tax Expense | (94K) | (26K) | (3K) | (33K) | (29.7K) | (31.2K) | |
| Research Development | 4.6M | 6.6M | 5.9M | 9.2M | 11.6M | 12.2M | |
| Net Income From Continuing Ops | (8.6M) | (10.9M) | (10.4M) | (13.9M) | (16.7M) | (15.8M) | |
| Non Operating Income Net Other | 1.9M | 7K | 94K | 26K | 29.9K | 28.4K | |
| Net Income Applicable To Common Shares | (8.6M) | (8.6M) | (10.9M) | (10.4M) | (9.4M) | (9.9M) | |
| Interest Income | 94K | 26K | 3K | 33K | 52K | 31.0K | |
| Net Interest Income | 94K | 26K | 3K | 33K | 52K | 32.5K | |
| Reconciled Depreciation | 230K | 151K | 161K | 178K | 183K | 198.9K |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.